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ABSTRACT
Objective: During peer review, submitted manuscripts
are scrutinised by independent experts to assist journal
editors in their decision-making and to help improve
the quality of articles. In this retrospective cohort
study, peer review comments for drug trials submitted
to medical journals were analysed to investigate
whether there is a relation between the content of
these comments and sponsorship, direction of results
and decision about acceptance.
Design/setting: Descriptive content analysis of
reviewer comments made on manuscripts on drug
trials submitted to eight medical journals ( January
2010–April 2012). For each manuscript, the number
of reviewers, decision about acceptance, sponsorship
and direction of results were extracted. Reviewer
comments were classified using a predefined
checklist.
Results: Reviewer reports for 246 manuscripts were
assessed. Industry-sponsored trials were more likely to
receive comments about lack of novelty (8.9%) than
industry-supported (2.5%) and non-industry trials
(6.1%, overall p=0.038). Non-industry trials more often
received comments about poor experimental design
(69.7%) than industry-supported (58.8%) and
industry-sponsored trials (52.9%, overall p=0.019).
Non-industry trials were also more likely to receive
comments regarding inappropriate statistical analyses
(28.4%) than industry-supported (23.5%) and
industry-sponsored trials (15.1%, overall p=0.006).
Manuscripts with negative results were more likely to
receive comments about inappropriate conclusions
(29.3%) than those with positive results (18.9%,
p=0.010). Rejected manuscripts had more often
received comments on the research question not being
clinically relevant (7.8%) than accepted manuscripts
(1.6%, p=0.002), and also on lack of novelty (8.3% vs
2.6%, p=0.008) and poor experimental design (68.6%
vs 50.5%, p<0.001).
Conclusions: Reviewers identified fewer
shortcomings regarding design and statistical analyses
in industry-related trials, but commented more often
on a lack of novelty in industry-sponsored trials.
Negative trial results did not significantly influence the
nature of comments other than appropriateness of the
conclusion. Manuscript acceptance was primarily
related to the research question and methodological
robustness of studies.
INTRODUCTION
At peer-reviewed medical journals, submitted
articles are sent out for external peer review
if they are considered to be potentially suit-
able for publication. During peer review,
manuscripts are scrutinised by independent
experts or peers in the same ﬁeld, to assist
editors in their decision-making and to help
improve the quality of submitted articles.1 2
The peer review process has been investi-
gated to a limited extent. Some studies
addressed the effects of blinding and train-
ing of reviewers, the detection rate of delib-
erately introduced errors by reviewers, and
the impact of peer review on the quality of
published articles.3–8
Strengths and limitations of this study
▪ Analysis of real life peer review comments on
submitted manuscripts in relation to sponsor-
ship, direction of results and decision about
acceptance.
▪ Inclusion of manuscripts submitted to a general
medical journal and specialty journals across dif-
ferent medical specialties.
▪ Comprehensiveness of classification checklist
assessed in two training sessions. Reviewer
comments for 20% of included manuscripts
scored by two raters and good level of inter-rater
agreement.
▪ Focus on reviewer comments made during initial
peer review of articles; additional comments may
have been raised during reviews of revised
versions.
▪ Reviewer comments may not inherently provide
an objective reflection of the quality of articles,
as there is evidence in the literature on the
defects of peer review.
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Few studies have systematically analysed the content of
reviewer comments on submitted articles. Bordage9
studied the reasons given by reviewers for rejection of
manuscripts submitted for publication in conference
proceedings on research in medical education.
Inappropriate statistics and overinterpretation of results
were commonly reported.9 Turcotte et al10 analysed
reviewer comments for manuscripts submitted to the
Canadian Journal of Anesthesia, and found that lack of
originality, inadequate experimental design and inappro-
priate conclusions were the main determinants of an
article’s fate. Hopewell et al7 focused on reviewer com-
ments on the reporting of methodological items in ran-
domised trials submitted to open peer review journals.
The type of changes requested by reviewers included
addition or clariﬁcation of randomisation, blinding, and
sample size, and toning down of conclusions to reﬂect
the results.7
The content of reviewer comments may be related to
the direction of results and sponsorship. Emerson et al11
compared reviewer reports for a fabricated manuscript
reporting positive results and an otherwise identical
manuscript reporting no effect. Reviewers detected
more errors in the no-difference version and awarded
higher scores to the methodology section of the positive
manuscript, although the methods sections were identi-
cal.11 Emerson et al11 showed that the positive article was
more often recommended for publication than the
no-difference version, although this observation could
not be conﬁrmed by others.12 None of the previous
studies on peer review compared reviewer comments
according to whether reported trials were sponsored by
pharmaceutical companies or non-proﬁt organisations.
Analysis of reviewer comments provides more insight
into the shortcomings of drug trials that are submitted
to medical journals, both from the perspective of the
design and conduct of trials and the reporting quality in
articles. It would be interesting to determine whether
the occurrence of speciﬁc shortcomings in manuscripts
is affected by sponsorship and results being either posi-
tive or negative. In the current study, we performed a
descriptive content analysis of peer review comments
made on manuscripts on drug trials submitted to eight
medical journals to investigate the relationship between
the content of comments and sponsorship, direction of
results, and decision about acceptance, using a previ-
ously reported cohort.13
METHODS
Journal and manuscript selection
We included manuscripts submitted from January 2010
through April 2012 to one general medical journal
(BMJ) and seven specialty journals (Annals of the
Rheumatic Diseases, British Journal of Ophthalmology,
Gut, Heart, Thorax (all from the BMJ Group),
Diabetologia, and Journal of Hepatology). We selected
randomised controlled trials, in which at least one study
arm assessed the efﬁcacy or safety of a drug and a statis-
tical test was used to evaluate treatment effects. This
cohort has been described in detail previously.13 This
study was limited to manuscripts that were sent out for
external peer review.
Data extraction manuscripts
For each manuscript, the decision about acceptance and
reviewer reports were extracted from submission systems
or provided by journals. Manuscripts were either
rejected after review or accepted for publication. We
determined the number of reviewers that evaluated the
ﬁrst submitted version of each article. Manuscripts could
be evaluated during multiple rounds of review before a
ﬁnal decision was made, but we focused on comments
that were made during initial peer review of articles.
Reviews of revised manuscripts were excluded.
Information on sponsorship and the direction of results
was previously extracted from manuscripts and classiﬁed
according to predeﬁned criteria.14 Reviewers were aware
of the sponsorship of trials. In short, trials were classiﬁed
as non-industry, industry-supported or industry-
sponsored trials. For non-industry trials, no associations
with pharmaceutical companies were reported. Studies
reporting donation of study medication by a manufac-
turer, studies stating receipt of ﬁnancial support from a
pharmaceutical company, and studies with industry-
afﬁliated authors were classiﬁed as industry-supported
trials. For industry-sponsored trials, a pharmaceutical
company was explicitly described as study sponsor, or
the company funding the trial participated in the
design, data collection, analysis and/or preparation of
the manuscript. Trial results were scored as positive if
results reported for the primary end point were statistic-
ally signiﬁcant (p<0.05 or 95% CI for difference exclud-
ing 0 or 95% CI for ratio excluding 1) and supported
the efﬁcacy of the test drug, and negative if they did not.
Results of non-inferiority trials were classiﬁed as positive
if treatments were equivalent. Safety trials were classiﬁed
as positive if the test drug was as safe as or safer than
control.
Classification of reviewer comments
A validated instrument for classiﬁcation of reviewer com-
ments does not exist. Included journals did not provide
standardised forms to reviewers, but general guidance
for peer review was available on each journals’ website.
Based on this guidance15–17 and previous research on
peer review,9 10 18–20 a classiﬁcation checklist for negative
reviewer comments was composed. In two consecutive
training sessions, reviewer comments for 10 randomly
selected manuscripts were independently classiﬁed by
two raters (MvL and HJO) in each session, to assess the
consistency between raters and check on the compre-
hensiveness of the checklist. Both after the ﬁrst and
second training session, disparities in the interpretation
of comments were discussed and the checklist was
revised accordingly. The ﬁnal version of the checklist
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(see online supplementary table S1) was then tested on
reviewer comments for a random sample of 30 manu-
scripts that were independently classiﬁed by the two
raters. Assuming an inter-rater agreement of at least
80% for each type of comment with the ﬁnal checklist,
30 manuscripts were sufﬁcient to estimate the agree-
ment with a precision (SE) of at most 7%. If the
inter-rater agreement during this test was considered suf-
ﬁciently high, a single reviewer (MvL) could continue
with the rating process. After the classiﬁcation of
reviewer comments for these 30 manuscripts, we calcu-
lated the percentage of agreement between raters for
each type of comment in the checklist. κ Statistics were
not considered suitable as some types of comments were
rarely scored and resulting κ values would be inaccur-
ate.21 For these 30 manuscripts, classiﬁcation discrepan-
cies were resolved by consensus between raters if the
agreement for a comment was <85%. For the other
types of comments, the score assigned by the rater who
subsequently classiﬁed all comments for the other
manuscripts (MvL) was decisive. Overall, reviewer com-
ments for 50 manuscripts were scored by two raters in
this study, which was equivalent to 20% (50 of 246) of
the total number of included manuscripts. For each
manuscript, a reviewer could have several remarks
related to one type of comment. However, each type of
comment was scored maximally once per reviewer.
Statistical analysis
Descriptive statistics were used to describe included
manuscripts (data presented as frequencies and percen-
tages). The relationship between each type of comment
and sponsorship, direction of results and decision about
acceptance was analysed using a generalised linear
mixed model based on generalised estimating equations
(GEE) with a binary distribution for the dependent vari-
able and an identity link. In this model, the comment
score of a reviewer (comment vs no comment) was used
as the dependent variable. We included sponsor type,
results or decision about acceptance as ﬁxed variable in
the model, and—if possible (if the model converged)—
journal, to control for the journal to which a manuscript
was submitted. The unique identiﬁcation number that
manuscripts received from a journal was included as
cluster variable (random effect). Most manuscripts were
reviewed by several reviewers. The model estimates the
percentage of reviewers that will comment on a manu-
script, depending on sponsor type, results or decision
about acceptance (‘mean percentage of comments on a
manuscript’). If a lower limit of the resulting CI was
negative, it was truncated to 0. The number of different
types of comments per manuscript was compared by
sponsorship, results or decision about acceptance using
univariate analysis of variance. We controlled for the
number of reviewers per manuscript by including this as
a covariate in the model. Two-sided p<0.05 was consid-
ered statistically signiﬁcant. p Values were not adjusted
for multiple comparisons. Statistical analyses were
performed using SPSS software (V.20) and SAS for
Windows (V.9.2, SAS Institute Inc).
Ethics
To assure conﬁdentiality of manuscripts and reviewer
reports, conﬁdentiality agreements were signed by the
authors before gaining access to the data. As standard
editorial and peer review processes were unchanged,
authors and reviewers were not informed about this
study. Research ethics committee (REC) approval was not
required as this study involved no human participants.
RESULTS
From January 2010 through April 2012, 472 manuscripts
on drug RCTs were submitted to eight journals, of which
250 articles (53.0%) were externally reviewed. For 246
manuscripts, reviewer comments for authors were avail-
able. Of these 246, 96 (39.0%) were accepted for publi-
cation (table 1). Eighty-nine (36.2%) were non-industry
trials, while 78 (31.7%) were industry-supported and 79
(32.1%) were industry-sponsored trials. Most articles
reported positive results (N=150, 61.0%). The number
of reviewers for the ﬁrst submitted version of an article
ranged from 1 to 5. In total, 575 reviewer reports were
evaluated.
Overall, the level of inter-rater agreement for the ﬁnal
version of the classiﬁcation checklist was good. For all
Table 1 Characteristics of included manuscripts
Manuscripts, n (%)
Total 246 (100)
Journal
BMJ 39 (15.9)
Annals of the Rheumatic
Diseases
44 (17.9)
British Journal of Ophthalmology 12 (4.9)
Gut 31 (12.6)
Heart 8 (3.3)
Thorax 23 (9.3)
Diabetologia 51 (20.7)
Journal of Hepatology 38 (15.4)
Decision about acceptance
Rejected after peer review 150 (61.0)
Accepted for publication 96 (39.0)
Sponsor type
Non-industry 89 (36.2)
Industry-supported 78 (31.7)
Industry-sponsored 79 (32.1)
Trial results
Positive results 150 (61.0)
Negative results 96 (39.0)
Number of reviewers per manuscript
1 10 (4.1)
2 160 (65.0)
3 61 (24.8)
4 13 (5.3)
5 2 (0.8)
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types of comments, the agreement between raters was
close to or higher than 80%. For 20 of 26 items,
there was >85% agreement (see online supplementary
table S2).
Overall, the types of comments that were most fre-
quently reported by reviewers included poor experimen-
tal design (range of point estimators in tables 2 and 3,
and 4; 50.5–69.7%), inadequately reported methods
(50.8–60.5%), incomplete study outcome data (58.7–
68.2%), inadequate discussion of the meaning of results
(44.2–56.1%), poor writing (34.7–42.8%) and inaccurate
tables or ﬁgures (35.1–44.1%). In table 2, the mean per-
centage of comments on a manuscript is compared by
sponsor type. For several types of comments, there was a
relation between sponsorship and the mean percentage
of comments. The percentage of comments regarding a
lack of novelty was signiﬁcantly associated with sponsor-
ship (p=0.038); industry-sponsored trials were more
likely to receive this comment (8.9%) than industry-
supported (2.5%) and non-industry trials (6.1%).
Table 2 Distribution of reviewer comments—by sponsor type
Mean percentage of comments on a manuscript (95% CI)*
Type of comment
Non-industry
(N=89)
Industry-supported
(N=78)
Industry-sponsored
(N=79) p Value
Importance
1. Research question not clinically relevant 6.3 (2.4 to 10.2) 6.1 (2.2 to 10.1) 3.3 (0.3 to 6.3) 0.372
Originality
2. Lack of novelty 6.1 (2.6 to 9.7) 2.5 (0.1 to 4.9) 8.9 (4.1 to 13.7) 0.038
Background and rationale
3. Incorrect background information 20.4 (15.2 to 25.5) 18.4 (12.2 to 24.6) 18.8 (12.5 to 25.2) 0.877
4. Poor justification for conducting study 1.5 (0.0 to 3.1) 2.8 (0.4 to 5.1) 6.3 (2.4 to 10.1) 0.081
Methods
5. Poor experimental design 69.7 (63.1 to 76.3) 58.8 (50.2 to 67.4) 52.9 (43.9 to 61.9) 0.019
6. Methods inadequately reported 60.5 (53.9 to 67.1) 54.7 (46.7 to 62.7) 50.8 (42.4 to 59.2) 0.209
7. Statistical analysis methods inappropriate 28.4 (22.3 to 34.6) 23.5 (16.4 to 30.5) 15.1 (10.1 to 20.2) 0.006
Results
8. Study outcome data incomplete 65.9 (59.4 to 72.4) 68.0 (59.7 to 76.4) 58.7 (50.6 to 66.8) 0.215
9. Flow of participants through study unclear 7.7 (3.8 to 11.6) 7.8 (3.3 to 12.4) 4.6 (1.8 to 7.4) 0.323
Discussion and conclusion
10. Meaning results inadequately discussed 44.2 (36.6 to 51.9) 46.7 (38.5 to 54.9) 56.1 (47.5 to 64.7) 0.090
11. Study insufficiently related to literature 15.2 (10.4 to 20.0) 15.5 (8.3 to 22.6) 8.7 (4.2 to 13.3) 0.180
12. Limitations not sufficiently discussed 17.2 (11.6 to 22.8) 19.9 (14.7 to 25.1) 13.8 (8.3 to 19.3) 0.223
13. Conclusions inappropriate 24.2 (17.7 to 30.6) 23.0 (16.0 to 30.1) 20.0 (13.2 to 26.8) 0.652
Abstract
14. Abstract does not correctly reflect paper 16.2 (11.5 to 20.9) 17.1 (11.8 to 22.4) 14.4 (8.8 to 19.9) 0.768
15. Discrepancies between the abstract and
the main text
2.0 (0.1 to 3.9) 0.6 (0.0 to 1.6) 1.0 (0.0 to 2.5) 0.443
References
16. References missing/irrelevant references
used
11.4 (7.0 to 15.8) 12.0 (6.6 to 17.4) 11.5 (6.1 to 16.8) 0.985
17. Errors in reference citation 1.5 (0.0 to 3.1) 1.7 (0.0 to 3.5) 4.6 (1.7 to 7.5) 0.159
Presentation
18. Title not representative of study 5.0 (1.7 to 8.2) 8.1 (3.3 to 12.8) 1.5 (0.0 to 3.1) 0.012
19. Poor writing 42.8 (35.5 to 50.2) 35.4 (27.9 to 42.9) 34.7 (26.8 to 42.6) 0.258
20. Inaccurate tables or figures 37.0 (30.9 to 43.1) 44.1 (36.5 to 51.7) 37.2 (29.5 to 45.0) 0.306
Ethics
21. Ethics committee approval not clear 2.0 (0.1 to 3.9) 1.7 (0.0 to 3.5) 2.1 (0.1 to 4.1) 0.951
22. Other ethical issues related to study 3.1 (0.0 to 6.3) 4.1 (0.7 to 7.5) 2.0 (0.1 to 4.0) 0.555
Trial registration, protocol, CONSORT
23. Registration/protocol/CONSORT missing 2.5 (0.4 to 4.6) 2.8 (0.4 to 5.1) 2.6 (0.4 to 4.8) 0.984
24. Deviations from registry or protocol 1.4 (0.0 to 3.3) 1.8 (0.0 to 3.8) 1.7 (0.0 to 3.6) 0.961
COI
25. Bias by author COIs/contribution funder
unclear
2.5 (0.4 to 4.6) 2.3 (0.1 to 4.4) 3.6 (1.1 to 6.2) 0.707
26. Systematic bias or spin in favour of
sponsor
0.0 (0.0 to 1.1) 0.5 (0.0 to 1.8) 1.7 (0.2 to 3.1) 0.139
*The mean percentage of comments on a manuscript is controlled for the journal to which a manuscript was submitted.
COI, conflicts of interest; N, number of submitted manuscripts.
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The percentage of comments regarding poor experi-
mental design was also associated with sponsorship
(p=0.019); non-industry trials more often received this
comment (69.7%) than industry-supported (58.8%) and
industry-sponsored trials (52.9%). Furthermore, the per-
centage of comments about inappropriate statistical ana-
lysis methods was associated with sponsorship (p=0.006);
non-industry trials were more likely to receive this
comment (28.4%) than industry-supported (23.5%) and
industry-sponsored trials (15.1%). The percentage of
comments regarding the article title not being represen-
tative of the study was also associated with sponsorship
(p=0.012); industry-supported trials more often received
this comment (8.1%) than non-industry (5.0%) and
industry-sponsored trials (1.5%).
In table 3, the mean percentage of comments on a
manuscript is compared by the direction of trial results.
For most types of comments, there was no signiﬁcant
difference according to whether manuscripts reported
positive or negative results. However, the percentage of
comments regarding inappropriate conclusions was
higher for articles with negative trial results (29.3%)
than for articles with positive results (18.9%, p=0.010).
Table 4 shows the mean percentage of comments on a
manuscript according to the decision about acceptance.
The percentage of comments about the research ques-
tion not being clinically relevant was higher among
rejected manuscripts (7.8%) than accepted manuscripts
(1.6%, p=0.002). Rejected manuscripts were more likely
to receive comments regarding a lack of novelty (8.3%)
Table 3 Distribution of reviewer comments—by direction of trial results
Mean percentage of comments on a manuscript (95% CI)*
Type of comment Negative results (N=96) Positive results (N=150) p Value
Importance
1. Research question not clinically relevant 4.3 (1.1 to 7.5) 5.9 (3.1 to 8.7) 0.469
Originality
2. Lack of novelty 3.5 (0.6 to 6.3) 7.4 (4.4 to 10.4) 0.066
Background and rationale
3. Incorrect background information 20.3 (14.9 to 25.8) 18.9 (14.5 to 23.3) 0.670
4. Poor justification for conducting study 4.2 (1.3 to 7.2) 3.0 (1.2 to 4.9) 0.497
Methods
5. Poor experimental design 64.9 (56.9 to 73.0) 60.0 (54.5 to 65.5) 0.285
6. Methods inadequately reported 55.4 (48.2 to 62.6) 56.3 (50.7 to 61.9) 0.844
7. Statistical analysis methods inappropriate 23.7 (17.3 to 30.1) 20.5 (15.7 to 25.3) 0.453
Results
8. Study outcome data incomplete 61.4 (53.5 to 69.2) 66.4 (61.0 to 71.8) 0.266
9. Flow of participants through study unclear 5.5 (2.3 to 8.8) 7.4 (4.5 to 10.3) 0.411
Discussion and conclusion
10. Meaning results inadequately discussed 47.8 (40.0 to 55.7) 48.5 (42.1 to 54.8) 0.889
11. Study insufficiently related to literature 12.6 (7.7 to 17.5) 13.7 (9.7 to 17.7) 0.748
12. Limitations not sufficiently discussed 14.4 (9.4 to 19.3) 18.4 (14.3 to 22.4) 0.203
13. Conclusions inappropriate 29.3 (22.6 to 36.0) 18.9 (14.0 to 23.9) 0.010
Abstract
14. Abstract does not correctly reflect paper 16.4 (11.4 to 21.4) 15.5 (11.8 to 19.2) 0.790
15. Discrepancies between the abstract and the main text 1.9 (0.1 to 3.6) 0.8 (0.0 to 1.8) 0.320
References
16. References missing/irrelevant references used 14.9 (9.8 to 20.0) 8.6 (5.8 to 11.5) 0.079
17. Errors in reference citation 2.3 (0.3 to 4.3) 2.8 (1.1 to 4.4) 0.731
Presentation
18. Title not representative of study 6.7 (2.5 to 10.9) 3.6 (1.7 to 5.5) 0.191
19. Poor writing 38.4 (31.4 to 45.4) 38.4 (32.5 to 44.3) 0.997
20. Inaccurate tables or figures 35.1 (28.6 to 41.6) 41.4 (36.1 to 46.7) 0.156
Ethics
21. Ethics committee approval not clear 1.4 (0.0 to 3.0) 2.2 (0.7 to 3.7) 0.463
22. Other ethical issues related to study 2.0 (0.1 to 3.9) 3.8 (1.4 to 6.2) 0.267
Trial registration, protocol, CONSORT
23. Registration/protocol/CONSORT missing 1.9 (0.1 to 3.6) 3.0 (1.3 to 4.8) 0.352
24. Deviations from registry or protocol 1.8 (0.0 to 4.0) 1.4 (0.2 to 2.7) 0.758
COI
25. Bias by author COIs/contribution funder unclear 1.9 (0.1 to 3.6) 3.3 (1.5 to 5.1) 0.254
26. Systematic bias or spin in favour of sponsor 0.0 (0.0 to 1.1) 1.0 (0.0 to 2.0) 0.120
*The mean percentage of comments on a manuscript is controlled for the journal to which a manuscript was submitted.
COI, conflicts of interest; N, number of submitted manuscripts.
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than accepted manuscripts (2.6%, p=0.008). In addition,
the percentage of comments about poor experimental
design was higher for rejected manuscripts (68.6%)
than for those that were accepted (50.5%, p<0.001).
Reviewers more often reported that a study was insufﬁ-
ciently related to the literature among manuscripts that
were accepted (18.6%) compared to those that were
rejected (10.5%, p=0.041).
In table 5, the number of different types of comments
per manuscript is shown, which was adjusted for the
number of reviewers per manuscript. Overall, reviewers
reported a mean number of 7.8 different types of com-
ments per manuscript (range, 1–15 types of comments).
The number of types of comments per manuscript was
not associated with the direction of results or the
decision about acceptance of manuscripts. There was a
signiﬁcant relation between sponsorship and the
number of different types of comments per manuscript
(p=0.035); non-industry trials on average received more
types of comments per manuscript (8.2) than industry-
sponsored trials (7.2).
DISCUSSION
This is the ﬁrst study in which real life peer review com-
ments made on submitted manuscripts were compared
according to sponsorship, direction of results and deci-
sion about acceptance. Previous studies have been
limited to experiments with ﬁctitious manuscripts.11 12
The most frequently reported comments by reviewers
Table 4 Distribution of reviewer comments—by decision about acceptance
Mean percentage of comments on a manuscript (95% CI)*
Type of comment Rejected (N=150) Accepted (N=96) p Value
Importance
1. Research question not clinically relevant 7.8 (4.5 to 11.1) 1.6 (0.0 to 3.5) 0.002
Originality
2. Lack of novelty 8.3 (4.9 to 11.6) 2.6 (0.6 to 4.7) 0.008
Background and rationale
3. Incorrect background information 20.3 (15.8 to 24.8) 18.0 (12.7 to 23.3) 0.491
4. Poor justification for conducting study 2.4 (0.8 to 4.1) 4.9 (1.9 to 7.9) 0.168
Methods
5. Poor experimental design 68.6 (63.3 to 73.9) 50.5 (42.8 to 58.2) <0.001
6. Methods inadequately reported 57.7 (51.8 to 63.6) 52.7 (45.5 to 59.9) 0.306
7. Statistical analysis methods inappropriate 21.8 (16.7 to 27.0) 20.8 (15.1 to 26.4) 0.793
Results
8. Study outcome data incomplete 62.4 (56.4 to 68.5) 68.2 (61.3 to 75.1) 0.178
9. Flow of participants through study unclear 8.2 (4.8 to 11.5) 4.8 (2.3 to 7.2) 0.110
Discussion and conclusion
10. Meaning results inadequately discussed 45.5 (39.1 to 51.9) 53.1 (45.6 to 60.6) 0.092
11. Study insufficiently related to literature 10.5 (7.1 to 14.0) 18.6 (13.0 to 24.2) 0.041
12. Limitations not sufficiently discussed 16.0 (12.3 to 19.8) 18.3 (12.8 to 23.8) 0.454
13. Conclusions inappropriate 23.1 (17.9 to 28.3) 21.8 (15.4 to 28.2) 0.755
Abstract
14. Abstract does not correctly reflect paper 15.7 (12.0 to 19.4) 16.1 (11.2 to 21.1) 0.891
15. Discrepancies between the abstract and the main text 1.5 (0.2 to 2.8) 0.8 (0.0 to 1.9) 0.419
References
16. References missing/irrelevant references used 11.6 (8.0 to 15.2) 11.6 (6.6 to 16.7) 0.990
17. Errors in reference citation 2.7 (1.0 to 4.4) 2.5 (0.6 to 4.3) 0.843
Presentation
18. Title not representative of study 6.2 (3.1 to 9.2) 2.9 (0.8 to 4.9) 0.080
19. Poor writing 37.5 (31.6 to 43.3) 40.0 (32.7 to 47.4) 0.555
20. Inaccurate tables or figures 36.7 (31.5 to 41.9) 43.3 (36.3 to 50.2) 0.121
Ethics
21. Ethics committee approval not clear 1.8 (0.4 to 3.2) 2.1 (0.3 to 3.8) 0.839
22. Other ethical issues related to study 4.1 (1.5 to 6.7) 1.6 (0.1 to 3.2) 0.115
Trial registration, protocol, CONSORT
23. Registration/protocol/CONSORT missing 3.0 (1.2 to 4.9) 2.0 (0.3 to 3.8) 0.435
24. Deviations from registry or protocol 2.2 (0.6 to 3.9) 0.8 (0.0 to 2.2) 0.217
COI
25. Bias by author COIs/contribution funder unclear 3.7 (1.7 to 5.6) 1.6 (0.1 to 3.2) 0.116
26. Systematic bias or spin in favour of sponsor 1.1 (0.1 to 2.1) 0.0 (0.0 to 0.9) 0.054
*The mean percentage of comments on a manuscript is controlled for the journal to which a manuscript was submitted.
COI, conflicts of interest; N, number of submitted manuscripts.
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included poor experimental design, inadequately
reported methods, incomplete study outcome data, inad-
equate discussion of the meaning of results, poor
writing, and inaccurate tables or ﬁgures, which is in line
with ﬁndings of previous studies.7 9 10 18 Reviewers rarely
reported on ethics, trial registration, or conﬂicts of inter-
est, as was expected from prior research.10 19 20
Submitted manuscripts on industry-sponsored trials
more often received comments regarding a lack of
novelty compared to industry-supported and non-
industry trials. However, we found no signiﬁcant differ-
ence according to sponsor type for comments on the
clinical relevance of research questions. It has been
argued in literature that studies by pharmaceutical com-
panies may be less innovative than non-industry studies.
Drug companies may more often focus on late-stage
drug development and producing variations of drugs
already on the market, while academia may be more
likely to perform creative, early-stage clinical
research.22 23 Interestingly, industry-supported trials were
least often criticised by reviewers for lack of novelty. This
may suggest that collaboration between academia and
the pharmaceutical industry could potentially lead to
more innovative clinical studies.
Non-industry trials were more likely to receive
comments regarding poor experimental design and
inappropriate statistical analysis methods than industry-
supported and industry-sponsored trials. In addition,
non-industry trials received signiﬁcantly more different
types of comments per manuscript than industry-
sponsored trials. Prior research based on published arti-
cles showed that the methodological quality of trials
funded by pharmaceutical companies was equal to or
tended to be higher than that of non-industry trials.24–27
Previously, we studied the shortcomings of protocols of
drug trials that were submitted for approval to RECs.28
Based on the comments raised during REC review, we
found that non-industry trials more often had
shortcomings regarding methodology and statistical ana-
lyses than industry-sponsored trials,28 which is in line
with ﬁndings of the current study.
Manuscripts with negative results were more likely to
receive comments regarding overinterpretation or
inappropriate conclusions in relation to results than
manuscripts with positive results. The number of types
of comments per manuscript was not associated with the
direction of results. Evidence of inconsistencies between
results and the interpretation of ﬁndings has previously
been shown for published articles, especially among
those with negative results.29 30 Authors may shape the
impression of results in articles, that is, to add ‘spin’ to
reports. Spin includes the use of speciﬁc reporting strat-
egies to highlight that the experimental treatment is
effective, despite non-signiﬁcant results for the primary
outcome, or to distract readers from non-signiﬁcant
results. This distorts the interpretation of results and
misleads readers.30 31
Rejected manuscripts had more often received com-
ments on the research question not being clinically rele-
vant, lack of novelty and poor experimental design than
accepted papers. The number of types of comments per
manuscript was not associated with decision about
acceptance though. Although we found signiﬁcant differ-
ences between comments for articles that were eventually
rejected or accepted, there are many reasons why papers
can get rejected beyond what is in reviewer reports for
the initial submitted version of manuscripts. Moreover,
editorial processes and the amount of weight put on
reviewer comments when making publication decisions
can be very variable across journals. Papers that reviewers
are positive about may be rejected, while others are pub-
lished despite of negative reviewer comments. As manu-
script review by journals is a complicated and multistage
process, it is difﬁcult to determine the exact inﬂuence of
reviewer comments in editorial decision-making.
This study is strengthened by the inclusion of
manuscripts submitted to a general medical journal and
specialty journals across different medical specialties.
The studies by Bordage9 and Turcotte et al10 were
limited to articles on research in medical education or
anaesthesia, which reduced the generalisability of their
ﬁndings. Hopewell et al included open peer review jour-
nals where reviewer comments are included alongside
published articles. Reviewers may more often provide
rather uncritical comments when reviewing for such
journals, as they may fear reprisals for criticising other
researchers’ work openly.7 32 In this study, we assessed
the comprehensiveness of the classiﬁcation checklist in
two training sessions. Reviewer comments for 20% of the
included manuscripts were scored by two raters and the
level of inter-rater agreement was good. In previous
studies, the classiﬁcation of reviewer comments was com-
pletely conducted by a single author.9 10
This study has some limitations. We focused on peer
review comments for the ﬁrst submitted version of arti-
cles. Some journals may send revised versions to new
Table 5 Number of different types of comments per
article
Mean number of types
of comments (95% CI)* p Value
Sponsor type 0.035
Non-industry 8.2 (7.6 to 8.8)†
Industry-supported 8.0 (7.4 to 8.6)
Industry-sponsored 7.2 (6.6 to 7.8)†
Trial results 0.794
Positive 7.8 (7.3 to 8.2)
Negative 7.9 (7.3 to 8.4)
Decision about
acceptance
0.145
Rejected 8.0 (7.6 to 8.5)
Accepted 7.5 (6.9 to 8.0)
*The mean number of types of comments per manuscript is
controlled for the number of reviewers per manuscript.
†The p value for the mean difference between non-industry and
industry-sponsored trials is <0.05.
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reviewers or back to the same reviewers. By focusing on
reviews of initial versions, new comments raised during
reviews of revisions may have been missed. However,
initial reviewer reports often contain the most extensive
comments and provide adequate information to
compare reviewer comments according to sponsorship,
direction of results and decision about acceptance. We
have not assessed whether shortcomings that were
detected by reviewers were corrected in revised manu-
scripts. Hopewell et al7 found that most authors com-
plied with requests by reviewers in their revised version,
but this was beyond the scope of this study. In addition,
we included a sample of manuscripts describing drug
RCTs and our results may therefore not be generalisable
to other study designs or RCTs with other interventions.
Although peer review is generally assumed to raise the
quality of submitted papers and to provide a mechanism
for rational and fair editorial decision-making,33 reviewer
comments may not automatically provide an objective
reﬂection of the quality of articles. While the evidence
on the effectiveness of peer review is limited,2 6 33 there
is considerable evidence on its defects.2 34 In studies
where major errors were inserted into papers that were
subsequently sent to reviewers, none of the reviewers
spotted all of the errors.4 35 In addition, it has been sug-
gested that peer review is a subjective and, therefore,
inconsistent process.34 Agreement between reviewers in
their recommendations for manuscripts may be low.36
Nevertheless, peer review is seen by researchers as
important and essential for scientiﬁc communication
and as the best alternative currently available.34 37
In conclusion, peer reviewers identiﬁed fewer short-
comings regarding design and statistical analyses in
industry-related trials, but commented more often on a
lack of novelty in industry-sponsored trials. Negative trial
results did not signiﬁcantly inﬂuence the nature of com-
ments other than appropriateness of the conclusion.
Manuscript acceptance was primarily related to the
research question and methodological robustness of the
study. As some of the manuscripts’ shortcomings repre-
sent fundamental methodological weaknesses, better
training on trial design and analysis may be appropriate,
especially for non-industry trials. Other errors are more
just omissions, including frequently reported shortcom-
ings such as inadequate reporting of methods and
incomplete reporting of study outcome data. These
ﬁxable errors can be avoided if authors pay more atten-
tion to reporting quality in manuscripts.
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